Veyonda Aids Radiation Therapy in Reaching Distant Lesions in Late-stage Cancer Trial
News
Veyonda (idronoxil) given in combination with low-dose radiation therapy was able to shrink metastatic lesions well outside the radiation field in about 27% of men with late-stage metastatic castration-resistant prostate cancer (mCRPC) in the DARRT-1 Phase ... Read more